-
The research finds that the medicine, called Paxlovid, was effective in preventing hospitalization and death when taken by people with mild to moderate illness within a few days of symptoms.
-
Pfizer researchers looking for a drug to treat SARS found clues that gave the company a head start in its quest for a pill to treat COVID-19, including the omicron variant.
-
Pfizer's CEO says the vaccine maker has asked federal regulators to authorize boosters for 16- and 17-year-olds. Currently, only people 18 and over are eligible for a booster in the U.S.
-
The FDA on Friday granted emergency use authorization for the Pfizer-BioNTech and Moderna booster shots. The boosters have already been available for people 65 and older and to high-risk adults.
-
Pfizer asked the FDA to authorize emergency use of the experimental pill, which has been shown to significantly cut the rate of hospitalizations and deaths among people with coronavirus infections.
-
The Food and Drug Administration is expected to announce later this week that it is authorizing boosters for people 18 or older, even if they aren't at risk for severe disease.
-
Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population.
-
The companies say a study of more than 10,000 volunteers showed a vaccine efficacy of 95% or greater for people receiving the booster.
-
Based on the strength of the trial's results, Pfizer says it will ask the FDA for emergency use authorization rather than enroll more people for clinical trials.
-
Millions of doses have already been shipped to states, doctors' offices and pharmacies. And pediatricians are getting ready to put shots into little arms. The shots contain a third of the dose given to teens and adults.